BSX Q2 Beat, but WATCHMAN and EP Softness Cut 2026 Growth to 5%-6%

Boston Scientific Beat Q2 Expectations, but the Lowered Guide Changed the Story

Boston Scientific delivered a solid second quarter, but the lowered 2026 outlook turns a good report into a wait-for-proof setup. The company posted $5.442 billion in Q2 sales, 7.0% organic revenue growth, and $0.86 adjusted EPS, beating expectations. The bigger message was forward-looking: BSX now expects 5% to 6% 2026 organic revenue growth and $3.28 to $3.32 of 2026 adjusted EPS, down from its prior 5.5% to 6.5% revenue guide and prior EPS guidance of $3.34 to $3.41.

The pullback is concentrated, not company-wide

Management tied the revised outlook mainly to WATCHMAN and U.S. electrophysiology pressure, two businesses that had been important growth drivers. That leaves room for the bullish case: the broader business still appears to be working. But it also creates a show-me scenario. Investors now need evidence that WATCHMAN stabilizes, EP pressure eases, and the stronger segments can carry enough of the load to rebuild confidence.

Segment mix explains why the quarter looked better than the guide

Strong pockets offset slower growth engines

Boston Scientific's second quarter was not uniform. Interventional Cardiology grew 15%, Neuromodulation grew 12%, Endoscopy grew 7%, and Vascular Therapies grew 8%. Those results show demand is still intact in several large lanes.

The guidance cut, however, reflects softer performance in businesses investors had counted on for incremental speed. WATCHMAN grew 4%, with 3% growth in the U.S. offset by 18% international growth. Cardiac Rhythm Management declined 2%. That mix matters: strong pockets kept the quarter respectable, but weaker pockets reduced what management felt comfortable guiding for.

WATCHMAN growth is being reshaped by procedure mix

The WATCHMAN issue is not just softer demand. Management said roughly one-third of U.S. WATCHMAN procedures are now concomitant, concomitant procedures rose more than 60% year over year, and standalone procedures declined by the low teens. That helps explain why the slowdown is unlikely to disappear after one quarter. Boston Scientific expects WATCHMAN growth to be flat to low single digits for the full year, with a mid- to high-single-digit decline in the second half, and management flagged margin pressure into 2027.

The debate: transition or slower earnings power?

Bulls can point out that electrophysiology still grew 9% in Q2, which argues against calling this a full breakdown. Bears will note that EP is now expected to be flat, with pressure extending into 2027. The practical question for investors is whether the stronger lanes can expand fast enough to offset WATCHMAN and EP friction. If they can, this looks more like a transition. If not, earnings power may stay tighter for longer.

Q3 matters because the earnings buffer is now more exposed

The bar is lower, but the room for error is smaller

Q3 is the first real test because Boston Scientific now expects Q3 organic revenue growth of 3% to 5% after a strong Q2. That narrows the runway and means investors can no longer rely on another obvious beat for comfort.

It also matters because management said the EPS outperformance was primarily driven by favorable tax results. That does not make the quarter weak, but it does mean the right lens is not sudden operating leverage. With growth slowing, existing margin has to do more of the work.

Margins and cash flow remain supportive, but they are not a free pass

Boston Scientific still posted a 70.3% adjusted gross margin, a 28.4% adjusted operating margin, and $1.29 billion in free cash flow in Q2. Those are strong figures. But they do not erase the warning that management flagged limited EPS growth and margin pressure into 2027. If slower WATCHMAN and EP lanes continue to weigh on mix, the company may need to lean more on cost control and cash conversion to protect per-share growth.

The reset program helps, but timing is still the issue

Boston Scientific also outlined a restructuring program aimed at approximately $500 million in annualized savings by the end of 2029, with more than half realized by the end of 2027. That can help support margins while the slowdown works through the system. The limitation is straightforward: savings can improve the earnings structure, but they do not create demand.

What investors should watch next

The next few quarters should make the picture clearer.

The main trigger

• Q3 is the key proof point. Boston Scientific has set the bar at Q3 organic revenue growth of 3% to 5% and adjusted EPS of $0.80 to $0.82. Meeting that range would suggest the company is absorbing the reset. Missing it would suggest the pressure may still be spreading.

What matters most

• Is EPS becoming more operationally driven rather than tax-assisted?
• Are the stronger segments still growing fast enough to offset slower WATCHMAN and EP performance?
• Are cost-cutting benefits arriving early enough to offset weaker mix?

What would suggest the market overreacted

• If EP performance improves materially from the current expectation of flat growth and WATCHMAN softness proves more temporary than durable, the slowdown may prove overdone.
• If margin performance near the 28.4% adjusted operating margin held in Q2 is sustained while growth reaccelerates, investors will have a stronger case for treating this as a reset rather than a broken thesis.

Near term, the setup still looks cautious rather than broken. The cleanest path to a more constructive view is Q3 execution.